2026-10-30 11:00:02 UTC#545105newconfirmednews
Vertex Pharmaceuticals (VRTX) stock news
Vertex Pharmaceuticals (VRTX) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-24 02:15:24 UTC#509567updateconfirmednews
Vertex Pharmaceuticals' povetacicept shows 52% proteinuria reduction in IgAN; AMPLITUDE interim data due early 2027
quartrimportance 0.50trust 0.70Vertex Pharmaceuticals Inc. +0.50Povetacicept +0.50AMPLITUDE +0.30+2 entities
2026-10-24 00:17:07 UTC#509469updateconfirmednews
Vertex Pharmaceuticals reports positive Week 36 RAINIER trial data for povetacicept; AMPLITUDE interim results due early 2027
quartrimportance 0.50trust 0.70Vertex Pharmaceuticals Inc. +0.60povetacicept +0.60RAINIER +0.60+1 entities
2026-10-23 17:42:00 UTC#508248newconfirmednews
Vertex Pharmaceuticals' povetacicept meets primary endpoint in Phase 3 RAINIER IgAN trial with 49.8% proteinuria reduction
tradingviewimportance 0.70trust 0.80Vertex Pharmaceuticals Incorporated +0.80povetacicept +0.80Food and Drug Administration +0.50
2026-10-20 21:57:27 UTC#489619newconfirmedpress release
Vertex Pharmaceuticals appoints Daniel Brennan to board, expands board size to 11 members
2026-10-09 17:15:00 UTC#439755newconfirmednews
Vertex reports interim ALYFTREK data in 2-5 year-olds showing potential for pancreatic function restoration
tradingviewimportance 0.40trust 0.70Vertex Pharmaceuticals Incorporated +0.40ALYFTREK +0.40North American Cystic Fibrosis Conference 0
2026-10-08 14:21:00 UTC#433060newconfirmednews
RBC Capital maintains Outperform rating on Vertex Pharmaceuticals
2026-10-01 12:01:00 UTC#398354newconfirmednews
Vertex Pharmaceuticals appoints Debanjan Saha to board of directors
2026-09-28 18:07:00 UTC#379500newconfirmednews
UBS Raises Vertex Pharmaceuticals (VRTX) Price Target to $615.00 From $585.00
2026-09-22 15:24:19 UTC#349980newconfirmednews
Vertex Pharmaceuticals reports positive mid-stage clinical trial results for inaxaplin in kidney disease
2026-09-21 11:28:15 UTC#342059newconfirmednews
Vertex Pharmaceuticals faces Nov. 30 PDUFA for povetacicept and upcoming pivotal readouts for inaxaplin
tradingviewimportance 0.40trust 0.60Vertex Pharmaceuticals Incorporated +0.40Crinetics Pharmaceuticals, Inc. +0.30povetacicept +0.40+2 entities
2026-09-11 13:30:24 UTC#298937duplicateconfirmednews
Vertex Pharmaceuticals trades higher following JPMorgan bullish rating upgrade
seeking alphaimportance 0.30trust 0.60Vertex Pharmaceuticals Incorporated +0.40JPMorgan Chase & Co. +0.40
2026-09-11 12:35:00 UTC#298556newconfirmednews
JPMorgan raises Vertex Pharmaceuticals (VRTX) price target to $560 from $515
dow_jonesimportance 0.30trust 0.70Vertex Pharmaceuticals Incorporated +0.30JPMorgan Chase & Co. +0.30
2026-09-09 21:56:39 UTC#288310newconfirmedanalysis
Vertex Pharmaceuticals (VRTX) growth outlook supported by upcoming renal and pain drug launches
2026-09-02 17:53:51 UTC#257712duplicateconfirmednews
Morgan Stanley resumes Vertex Pharmaceuticals coverage with Overweight rating and $665 price target
seekingalpha.comimportance 0.40trust 0.70Vertex Pharmaceuticals, Inc. +0.50Morgan Stanley +0.40Crinetics Pharmaceuticals, Inc. +0.30+2 entities
2026-09-02 17:53:51 UTC#257703newconfirmednews
Morgan Stanley resumes coverage of Vertex Pharmaceuticals with Overweight rating
seeking alphaimportance 0.40trust 0.70Vertex Pharmaceuticals Incorporated +0.40Morgan Stanley +0.30Crinetics Pharmaceuticals, Inc. 0
2026-09-02 10:43:00 UTC#254840newconfirmednews
Morgan Stanley sets $665.00 price target on Vertex Pharmaceuticals (VRTX)
2026-09-02 05:54:59 UTC#253604newconfirmednews
Goldman Sachs adds Vertex, RWE, and Adyen to September conviction lists
seeking alphaimportance 0.40trust 0.60Vertex Pharmaceuticals Incorporated +0.40RWE AG +0.40Adyen N.V. +0.40+1 entities
2026-09-01 13:56:00 UTC#249717duplicateconfirmednews
Vertex Pharmaceuticals names Jonathan Poole CFO as $10B Crinetics acquisition closes
dow_jonesimportance 0.30trust 0.90Vertex Pharmaceuticals, Inc. +0.20Crinetics Pharmaceuticals, Inc. +0.20Jonathan Poole +0.10+2 entities
2026-09-01 13:41:00 UTC#249541duplicateconfirmednews
Vertex Pharmaceuticals names Jonathan Poole as CFO following $10B Crinetics acquisition completion
dow_jonesimportance 0.30trust 0.90Vertex Pharmaceuticals Inc. +0.30Crinetics Pharmaceuticals, Inc. +0.20Jonathan Poole +0.10+2 entities